ALLAKOS INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • June 22nd, 2018 • Allakos Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of _______, 2018 and is between Allakos Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”).
Allakos Inc. 29,882,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • September 19th, 2022 • Allakos Inc. • Pharmaceutical preparations • New York
Allakos Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 29,882,000 shares (the “Shares”).
ALLAKOS INC. SALES AGREEMENTSales Agreement • August 5th, 2022 • Allakos Inc. • Pharmaceutical preparations • New York
Allakos Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
LEASE AGREEMENTLease Agreement • June 22nd, 2018 • Allakos Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 1st day of May, 2013, between ARE-SAN FRANCISCO NO. 29, LLC, a Delaware limited liability company (“Landlord”), and ALLAKOS, INC., a Delaware corporation (“Tenant”).
LEASE AGREEMENT By and Between WESTPORT OFFICE PARK, LLC, a California limited liability company (“Landlord”) and ALLAKOS INC., a Delaware corporation (“Tenant”) January 4, 2018Lease Agreement • June 22nd, 2018 • Allakos Inc. • Pharmaceutical preparations • California
THIS LEASE AGREEMENT, (this “Lease”) is made and entered into as of January 4, 2018 by and between WESTPORT OFFICE PARK, LLC, a California limited liability company (“Landlord”), and Tenant identified in the Basic Lease Information below.
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Exclusive License Agreement • July 9th, 2018 • Allakos Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (“JHU”) and ALLAKOS INC., a Delaware corporation having an address at 75 Shoreway Road, Suite A, San Carlos, CA 94070 (“Company”), as of September 30, 2016 (the “Restatement Date”) and amends and restates that certain Exclusive License Agreement entered into by and between JHU and Allakos as of the Effective Date (the “Original License Agreement”), with respect to the following:
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Non-Exclusive License Agreement • July 9th, 2018 • Allakos Inc. • Pharmaceutical preparations
THIS NON-EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of October 31, 2013 (the “Effective Date”), is entered into by and between BioWa, Inc., with a principal place of business at 9420 Athena Circle, La Jolla, California 92037 USA (“BioWa”), Lonza Sales AG a Swiss corporation, with a principal place of business at Munchensteinerstrasse 38, Basel, CH-4002 Switzerland (“Lonza”) (together “the Licensor”) and Allakos, Inc. with its principal place of business located at 75 Shoreway Road, Suite A San Carlos CA 94070 (“Licensee”). Lonza, BioWa, Licensor or Licensee may hereafter be referred to as a “Party” and collectively as the “Parties.”
ALLAKOS INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT November 30, 2017Investors’ Rights Agreement • July 9th, 2018 • Allakos Inc. • Pharmaceutical preparations • California
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) made as of November 30, 2017, by and among Allakos Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A (each, an “Investor” and collectively, the “Investors”).
ALLAKOS INC. WAIVER OF REGISTRATION RIGHTS DATED AS OF OCTOBER 27, 2020Allakos Inc. • November 2nd, 2020 • Pharmaceutical preparations
Reference is hereby made to that certain Amended and Restated Investors’ Rights Agreement, dated as of November 30, 2017, as amended to date (the “Investors’ Rights Agreement”), by and among Allakos Inc., a Delaware corporation (the “Company”), and the Investors named therein (such Investors include each of the undersigned Holders of Registrable Securities). All capitalized terms used in this Waiver of Registration Rights (this “Waiver”) have the meanings ascribed to such terms in the Investors’ Rights Agreement unless otherwise defined herein. This Waiver shall be dated as of the date on which the Company or its agents receive the last signed counterpart signature page hereto necessary to give effect to the actions contemplated hereby.
LEASE AGREEMENTLease Agreement • February 25th, 2020 • Allakos Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 4th day of December, 2019, between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ALLAKOS INC., a Delaware corporation (“Tenant”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • December 11th, 2020 • Allakos Inc. • Pharmaceutical preparations • California
This Separation Agreement and Release (“Agreement”) is made by and between Leo Redmond (“Employee”) and Allakos Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
Certain identified information has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.***Supply Agreement • March 1st, 2021 • Allakos Inc. • Pharmaceutical preparations • New York
WHEREAS, Customer is engaged in the development, research and sale of certain products and requires assistance in the manufacture of Product;
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Non-Exclusive License Agreement • July 17th, 2018 • Allakos Inc. • Pharmaceutical preparations
THIS NON-EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of October 31, 2013 (the “Effective Date”), is entered into by and between BioWa, Inc., with a principal place of business at 9420 Athena Circle, La Jolla, California 92037 USA (“BioWa”), Lonza Sales AG a Swiss corporation, with a principal place of business at Munchensteinerstrasse 38, Basel, CH-4002 Switzerland (“Lonza”) (together “the Licensor”) and Allakos, Inc. with its principal place of business located at 75 Shoreway Road, Suite A San Carlos CA 94070 (“Licensee”). Lonza, BioWa, Licensor or Licensee may hereafter be referred to as a “Party” and collectively as the “Parties.”
DATED Termination wind-down and settlement Agreement among Lonza AG and Lonza Sales AG and Allakos Inc.Certain • March 1st, 2022 • Allakos Inc. • Pharmaceutical preparations • New York
July 6, 2018Letter Agreement • July 9th, 2018 • Allakos Inc. • Pharmaceutical preparations
This letter agreement (the “Agreement”) is entered into between you and Allakos Inc. (the “Company” or “we”), effective as of the date set forth above (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
ALLAKOS INC. $400,000,000 SALES AGREEMENTSales Agreement • May 10th, 2021 • Allakos Inc. • Pharmaceutical preparations • New York
Allakos Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
FIRST AMENDMENT TO LEASELease • May 9th, 2023 • Allakos Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of November 15, 2022, by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ALLAKOS INC., a Delaware corporation (“Tenant”).
SECOND AMENDMENT TO LEASELease • May 9th, 2023 • Allakos Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of March 27, 2023, and effective as of January 1, 2022 (the “Effective Date”), by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ALLAKOS INC., a Delaware corporation (“Tenant”).
1K Commercial Supply AgreementAllakos Inc. • May 11th, 2020 • Pharmaceutical preparations • New York
WHEREAS, Customer is engaged in the development, research and sale of certain products and requires assistance in the manufacture of Product;
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • April 20th, 2022 • Allakos Inc. • Pharmaceutical preparations • California
This Separation Agreement and Release (“Agreement”) is made by and between Mark Asbury (“Employee”) and Allakos Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 9th, 2018 • Allakos Inc. • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of December 5, 2012 by and between Allakos Inc. (the “Company”) and Dr. Christopher Bebbington (the “Employee”). The Company and the Employee are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Exclusive License Agreement • July 17th, 2018 • Allakos Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (“JHU”) and ALLAKOS INC., a Delaware corporation having an address at 75 Shoreway Road, Suite A, San Carlos, CA 94070 (“Company”), as of September 30, 2016 (the “Restatement Date”) and amends and restates that certain Exclusive License Agreement entered into by and between JHU and Allakos as of the Effective Date (the “Original License Agreement”), with respect to the following:
